



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_47264
Title of the Manuscript:	Interaction of cyclosporine with pomegranate juice and its potential nephroprotective effect in rats
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	The experimental design should be well stated and outlined. The groupings of the rats should be stated.	
Minor REVISION comments	Abstract Line 2: What is P-gp? Line 4: *This study aims at examining* instead as *this study aims to examine* Lines 6-9 : Why two separate studies, one for 5 days and next study for 28 days? Line 6: The first dose of 20mg/kg of cyclosporine given for 5days , was it given daily? Line 6: Specify the route of administration used? Not orally or SC Line 6: What is SC? Line 7: Why the pomegranate or distilled water? Please specify *** NO number of male wistar rats used? Please specify for this research. Line 8-9 : Please explain vividly what you did. Who did you design your research work? Line 13; This study provided evidence On the other hand. Please the statement is incomplete. Line 14: Remove *prevented* Introduction Line 7: No citation after practice? Materials and Method Preparation of pomegranate juice: *** No Acute Toxicity testing(LD ₅₀ ***The experimental rats are not grouped and indication as to what group received what drug treatment. These should be stated. Histopathology assessment Line 3: remove *ded* a) Statistical analysis Line 5; check the spelling * Tukey's * Conclusion Line 4: repeated administration . OF what drug?	T
	The statistical tables and the histological results figures should be brought within the body of the work for easier assessment, not in appendix except otherwise stated by the journal.	

PART 2:



SDI Review Form 1.6

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	<i>Idorenyin Umoh</i>
Department, University & Country	<i>University of Uyo, Nigeria</i>